Advertisement ATMI acquires LevTech for $27 million - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

ATMI acquires LevTech for $27 million

ATMI has acquired LevTech, a provider of disposable mixing technologies to the biotechnology and pharmaceutical industries, in a $27 million cash transaction.

Based in Lexington, Kentucky, LevTech will be combined with ATMI’s existing LifeSciences business focused on single-use bioprocess containers and processes for the biopharmaceutical industry.

Doug Neugold, CEO of ATMI, said: “The addition of LevTech’s innovative products, intellectual property, and market share puts ATMI’s LifeSciences business in a preeminent position for single-use manufacturing applications in the biopharmaceutical market.”